2019年11月
Clinical Utility of Highly Purified 10% Liquid Intravenous Immunoglobulin in Kawasaki Disease.
The Journal of pediatrics
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 214
- 号
- 開始ページ
- 227
- 終了ページ
- 230
- 記述言語
- 英語
- 掲載種別
- 研究論文（学術雑誌）
- DOI
- 10.1016/j.jpeds.2019.06.018
Compared with a 5% intravenous immunoglobulin, a 10% intravenous immunoglobulin as the first-line treatment of Kawasaki disease significantly reduced the fever duration (10 vs 13 hours, P = .022) among the responders, and the interval to adjunctive therapy for nonresponders (47 vs 49 hours, P = .035). There were no severe adverse events.
- リンク情報
- ID情報
-
- DOI : 10.1016/j.jpeds.2019.06.018
- PubMed ID : 31351682